Bone marrow, mobilized peripheral blood, and cord blood are all sources of hematopoietic and immune cells. Each source has advantages and disadvantages for hematopoietic transplantation. This session reviews current data and explores the role of each of these stem cell sources. Peripheral blood stem cells (PBSCs) are increasingly being used for related and unrelated donor hematopoietic stem cell transplantation. Collection of PBSCs rather than bone marrow (BM) offers several advantages to the donor, including avoidance of anesthesia, hospitalization, and potential exposure to blood products, although controlled comparisons of PBSC and BM donation do not indicate substantial differences in serious adverse effects. There are numerous reports, including randomized trials, comparing recipient outcomes after PBSC and BM transplantation from HLA-matched sibling donors, but the median follow-up of surviving patients is less than 3 years. Most data support a higher risk of chronic graft-versus-host disease with PBSCs than with BM grafts, and some support a survival advantage with PBSCs in recipients of transplantation for advanced leukemia. A convincing survival advantage for those with early leukemia has not yet been documented. Despite increasing numbers of unrelated donor PBSC transplantations, there are few reports describing outcomes in these groups of patients and none supporting a survival advantage for acute or chronic leukemia among PBSC recipients.
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The Center for International Blood and Marrow Transplant Research (CIBMTR), in collaboration with the European Group for Blood and Marrow Transplantation (EBMT), examined long-term outcomes after PBSC and BM transplantation in patients with acute and chronic leukemia. The first report with a median follow-up of 1 year showed higher chronic GVHD, lower transplantation-related mortality, and greater leukemia-free survival in patients with advanced leukemia at the time of transplantation [1] . Long-term follow-up data were obtained for 413 of 491 patients who were alive at the time of the initial report: 141 PBSC recipients and 272 BM recipients, with a median follow-up of more than 6 years [2] . Consistent with the initial report, chronic GVHD was Figure 1 . Probability of leukemia-free survival in patients with chronic leukemia after BM and PBSC transplants adjusted for disease status at transplantation (N ϭ number of evaluable patients; % ϭ the 6-year rate of leukemia-free survival). .1016/j.bbmt.2006.11.006 more frequent after PBSC transplantation than after BM transplantation (relative risk ϭ 1.65; P Ͻ .0001), yet relapse rates were similar in both groups. Leukemia-free survival rates were higher after PBSC transplantation than after BM transplantation for patients with advanced chronic myeloid leukemia (33% vs 25%) but lower for those in the first chronic phase (41% vs 61%) due to higher rates of late transplantation-related mortality (Figure 1) . Leukemia-free survival was similar after PBSC transplantation and BM transplantation for acute leukemia (Figure 2 ). These data represent the early experience with PBSC grafts. Nevertheless, this is the first report describing longterm outcomes after PBSC transplantation and indicates that although patients with advanced chronic leukemia may benefit from PBSC grafts, those with acute leukemia or early chronic leukemia may not. These findings should be validated with long-term follow-up of patients enrolled in randomized studies.
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Because few studies have examined the benefits of using PBSC grafts versus BM grafts for unrelated donor transplantation, the CIBMTR compared outcomes after 451 PBSC transplantations and 781 BM transplantations in adults with leukemia and myelodysplastic syndrome followed for a median of 3 years after transplantation [3] . Rates of grades 2-4 acute GVHD (56% vs 46%; P ϭ Ͻ .001), but not grade 3-4 acute GVHD, were higher after PBSC transplantation than after BM transplantation. Chronic GVHD was more frequent with PBSC transplantation than with BM transplantation (54% vs 40%; P Ͻ .001). The 3-year probabilities of treatment-related mortality, leukemia recurrence, leukemia-free survival, and overall survival were similar in the 2 groups; 3-year leukemia-free survival rates were 29% after PBSC transplantation and 31% after BM transplantation (Figure 3) . Unlike for results after HLA-matched sibling donor PBSC transplantation, we were unable to identify a survival advantage in patients with advanced leukemia. The higher rate of chronic GVHD after PBSC transplantation and, consequently, more frequent late adverse events warrant extended follow-up of these PBSC recipients, which is planned. Probability of leukemia-free survival in patients with acute leukemia after BM and PBSC transplants adjusted for disease status at transplantation (N ϭ number of evaluable patients; % ϭ the 6-year rate of leukemia-free survival).
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